Cargando…
Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518240/ https://www.ncbi.nlm.nih.gov/pubmed/30978937 http://dx.doi.org/10.3390/jcm8040489 |
_version_ | 1783418419194888192 |
---|---|
author | Sakamoto, Shinichi Maimaiti, Maihulan Xu, Minhui Kamada, Shuhei Yamada, Yasutaka Kitoh, Hiroki Matsumoto, Hiroaki Takeuchi, Nobuyoshi Higuchi, Kosuke Uchida, Haruhito A. Komiya, Akira Nagata, Maki Nakatsu, Hiroomi Matsuyama, Hideyasu Akakura, Koichiro Ichikawa, Tomohiko |
author_facet | Sakamoto, Shinichi Maimaiti, Maihulan Xu, Minhui Kamada, Shuhei Yamada, Yasutaka Kitoh, Hiroki Matsumoto, Hiroaki Takeuchi, Nobuyoshi Higuchi, Kosuke Uchida, Haruhito A. Komiya, Akira Nagata, Maki Nakatsu, Hiroomi Matsuyama, Hideyasu Akakura, Koichiro Ichikawa, Tomohiko |
author_sort | Sakamoto, Shinichi |
collection | PubMed |
description | Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan–Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan–Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients. |
format | Online Article Text |
id | pubmed-6518240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65182402019-05-31 Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer Sakamoto, Shinichi Maimaiti, Maihulan Xu, Minhui Kamada, Shuhei Yamada, Yasutaka Kitoh, Hiroki Matsumoto, Hiroaki Takeuchi, Nobuyoshi Higuchi, Kosuke Uchida, Haruhito A. Komiya, Akira Nagata, Maki Nakatsu, Hiroomi Matsuyama, Hideyasu Akakura, Koichiro Ichikawa, Tomohiko J Clin Med Article Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan–Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan–Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients. MDPI 2019-04-11 /pmc/articles/PMC6518240/ /pubmed/30978937 http://dx.doi.org/10.3390/jcm8040489 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sakamoto, Shinichi Maimaiti, Maihulan Xu, Minhui Kamada, Shuhei Yamada, Yasutaka Kitoh, Hiroki Matsumoto, Hiroaki Takeuchi, Nobuyoshi Higuchi, Kosuke Uchida, Haruhito A. Komiya, Akira Nagata, Maki Nakatsu, Hiroomi Matsuyama, Hideyasu Akakura, Koichiro Ichikawa, Tomohiko Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title | Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title_full | Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title_fullStr | Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title_full_unstemmed | Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title_short | Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer |
title_sort | higher serum testosterone levels associated with favorable prognosis in enzalutamide- and abiraterone-treated castration-resistant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518240/ https://www.ncbi.nlm.nih.gov/pubmed/30978937 http://dx.doi.org/10.3390/jcm8040489 |
work_keys_str_mv | AT sakamotoshinichi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT maimaitimaihulan higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT xuminhui higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT kamadashuhei higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT yamadayasutaka higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT kitohhiroki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT matsumotohiroaki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT takeuchinobuyoshi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT higuchikosuke higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT uchidaharuhitoa higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT komiyaakira higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT nagatamaki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT nakatsuhiroomi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT matsuyamahideyasu higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT akakurakoichiro higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer AT ichikawatomohiko higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer |